Emerging Peptide Therapies for Kidney Disease: Focus on Nano-Organo and Mitochondria-Targeted Strategies

💡 What’s Inside?
This cutting-edge review explores two next-generation peptide platforms: Nano-Organo Peptides (NOPs) and Mitochondria-Targeted Peptides (MTPs) as precision therapies for Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD).

📌 Key Highlights:
✔️ Nano-Organo Peptides (NOPs): Deliver peptides to subcellular compartments (e.g., mitochondria, lysosomes, ER) for targeted renal repair
✔️ Mitochondria-Targeted Peptides (MTPs): Protect kidney mitochondria by stabilizing cardiolipin, reducing oxidative stress, and restoring bioenergetics
✔️ Promising results in fibrosis attenuation, immune modulation, glomerular protection, and tubular cell survival
✔️ Therapeutic examples like SS-31 (elamipretide) show effectiveness in ischemia-reperfusion injury, diabetic nephropathy, and age-related renal decline
✔️ Highlights early clinical studies, renal-targeted delivery strategies, and emerging precision nephrology applications

This review outlines the scientific rationale, delivery systems, mechanistic targets, and clinical potential of peptide-based therapeutics in nephrology, opening new pathways for overcoming the limitations of conventional kidney treatments.

MORE PUBLICATIONS:
https://european-wellness.eu/publications/